Relief Therapeutics Holding SA

Equities

RLF

CH1251125998

Biotechnology & Medical Research

End-of-day quote Swiss Exchange 06:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
1.285 CHF +1.98% Intraday chart for Relief Therapeutics Holding SA +1.98% -35.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Sector Update: Health Care MT
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product MT
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike MT
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE CI
Relief Therapeutics Extends CHF50 Million Share Subscription Facility with Largest Shareholder MT
Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor CI
Relief Therapeutics to Run Commercial Operations Via Partnership Model MT
Relief Therapeutics CEO to Leave; Interim Successor Takes Over MT
Relief Therapeutics Holding Sa Announces CEO Changes CI
Relief Therapeutics Meets Outstanding ADR Requirement for Nasdaq Listing MT
Relief Therapeutics Holding AG(SWX:RLF) dropped from S&P Global BMI Index CI
Relief Therapeutics Holding AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Relief Therapeutics Posts Wider H1 Loss; Revenue Down MT
Relief Therapeutics Sells License for Urea Cycle Disorder Drug to Acer Therapeutics MT
Relief Therapeutics Holding AG Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics CI
Relief Therapeutics Announces Extension of Distribution Agreement for Pku Golike®? in the U.S. with Pentec Health CI
Relief Therapeutics Extends US Distribution Deal with Pentec Health for PKU GOLIKE MT
SIX Group Makes Index Adjustments Following Review MT
Relief Therapeutics Entrusts Middle Eastern Distribution of PKU GOLIKE to World Orphan Drug Alliance MT
Relief Therapeutics Secures CHF5 Million Capital Injection from Healthcare-focused Investor MT
Relief Therapeutics Holding AG announced that it has received CHF 4.9947 million in funding CI
Relief Therapeutics Targets CHF5 Million Gross Proceeds via Private Placement MT
Relief Therapeutics Holding AG announced that it expects to receive CHF 4.995 million in funding CI
Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding CI
Chart Relief Therapeutics Holding SA
More charts
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock Market
  2. Equities
  3. RLF Stock
  4. News Relief Therapeutics Holding SA
  5. Relief Therapeutics Extends CHF50 Million Share Subscription Facility with Largest Shareholder